We compared the CSF1R inhibitor sensitivity across CLL primary patient specimens with various clinical and genetic characteristics (Figure 2 and Supplementary Figure 1E-1P). The gene discussed is CSF1R; the disease is B-cell chronic lymphocytic leukemia.